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Abstract Parkinson’s disease (PD) is characterized by dopa-
minergic (DA) neuron death in the substantia nigra (SN) and
subsequent striatal adaptations. Mice treated with the neuro-
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine
(MPTP) are widely used as a model for PD. To assess the
validity of the MPTP mouse model for PD pathogenesis, we
here identify the biological processes that are dysregulated in
both human PD and MPTP-treated mice. Gene enrichment
analysis of published differentially expressed messenger
RNAs (mRNAs) in the SN of PD patients and MPTP-treated
mice revealed an enrichment of gene categories related to
motor dysfunction and neurodegeneration. In the PD striatum,
a similar enrichment was found, whereas in the striatum of
MPTP mice, acute processes linked to epilepsy were selec-
tively enriched shortly following MPTP treatment. More im-
portantly, we integrated the proteins encoded by the differen-
tially expressed mRNAs into molecular landscapes showing
PD pathogenesis-implicated processes only in the SN, includ-
ing vesicular trafficking, exocytosis, mitochondrial apoptosis,
and DA neuron-specific transcription, but not in the striatum.
We conclude that the current use of the MPTP mouse as a
model for studying the molecular processes in PD pathogen-
esis is more valid for SN than striatal mechanisms in PD. This
novel insight has important practical implications for future
studies using this model to investigate PD pathogenesis and
evaluate the efficacy of new treatments.
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Introduction
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a tox-
ic impurity that may occur during the synthesis of the opioid
drug desmethylprodine, causes an irreversible parkinsonian
syndrome in humans almost indistinguishable from
Parkinson’s disease (PD) [1]. Therefore, MPTP toxicity in
monkeys, rats, and mice has been studied to elucidate the
pathogenic mechanisms implicated in PD.MPTP-treatedmice
are advantageous to explore the molecular background of
MPTP toxicity, because lines of genetically engineered ani-
mals allow high levels of control of the experimental condi-
tions. Mice treated with MPTP share specific biological fea-
tures with PD, including loss of dopaminergic (DA) neurons
in the substantia nigra (SN) and dopamine depletion in the
striatum [2]. However, their pathogenetic backgrounds are
different, being a toxic nature in a mouse model and a neuro-
degenerative process in human PD. Moreover, not all PD
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phenomenology is reproduced in MPTP-treated mice [3].
Therefore, the construct validity of the MPTP mouse as a
model to study and elucidate the pathogenesis of PD remains
unclear.
In order to identify the biological processes that are dys-
regulated in MPTP toxicity and their relationship to PD path-
ogenesis, differentially expressed messenger RNAs (mRNAs)
from postmortem SN and striatum of PD patients, as well as
differentially expressed mRNAs in the SN and striatum of
MPTP-treated mice, were analyzed. Furthermore, based on
proteins encoded by the mRNAs that were differentially
expressed in both PD patients and MPTP mice, molecular
landscapes of interacting proteins were built for both the SN
and striatum. These landscapes represent molecular mecha-
nisms that are shared between PD and MPTP toxicity.
Together, these analyses will help to understand and value
experimental findings in the MPTP mouse in the light of hu-
man PD pathogenesis.
Materials and Methods
Genome-Wide mRNA Expression Data
Available genome-wide mRNA expression data frommultiple
previously published studies were used to generate a list of
differentially expressed transcripts in the postmortem SN and
striatum of PD patients and MPTP-treated mice, studied at
various time points following MPTP treatment. If raw expres-
sion data was available at the Gene Expression Omnibus
(GEO) site, this data was reanalyzed in GeneSifter (www.
genesifter.com) using robust microarray analysis (RMA).
The Benjamini-Hochberg method was then used to correct
for multiple comparisons, and only mRNAs with a fold
change (FC) of ≥1.2 or ≤−1.2 and a corrected p value <0.05
were considered to be differentially expressed and used for the
subsequent gene enrichment analysis, as described below. If
no raw data was available, our inclusion criteria were the
following: (1) correction for multiple testing was performed,
with a corrected p value <0.05 and the correction method was
explicitly mentioned; and (2) an mRNA expression FC of
≥1.2 or ≤−1.2. Only protein-coding mRNAs were included
in our analyses.
Enrichment Analysis
The Ingenuity pathway analysis software package (www.
ingenuity.com) was used to identify enriched gene categories
in the lists of differentially expressed mRNAs in the SN and
striatum of both human PD patients and MPTP-treated mice
and in the lists of overlapping mRNAs that were differentially
expressed in the SN or striatum of both PD patients andMPTP
mice. Ingenuity assigns genes and their corresponding
mRNAs/proteins to (sub)categories of functional classes, e.g.,
“diseases and disorders” and “molecular and cellular functions.
” For these analyses, only functional categories and pathways
with significant enrichment (i.e., Benjamini-Hochberg
corrected p<0.05) and containing two or more genes were
taken into account.
Molecular Landscape Building
Subsequently, the mRNAs that were differentially expressed
in the SN and striatum of both PD patients and MPTP-treated
mice were analyzed in more depth. Guided by the results of
the Ingenuity enrichment analyses, the literature was searched
for the (putative) function of all the proteins encoded by the
mRNAs overlapping between human PD and the MPTP
mouse, as well as their functional interactions, using the
UniProt Knowledgebase (http://www.uniprot.org/uniprot) [4]
and PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez).
Based on these findings and applying an approach similar to
the one we used previously to build landscapes based on
genome-wide association data [5, 6], we then built two mo-
lecular landscapes comprising interacting proteins encoded by
the overlapping mRNAs in the SN and striatum, respectively.
To complement these protein interaction cascades, we also
added a number of proteins that were not encoded by the
overlapping differentially expressed mRNAs but that have
been implicated in PD etiology through other lines of
(genetic) evidence. In this respect, proteins encoded by famil-
ial PD candidate genes were included if they have at least one
functional interaction with one or more other landscape pro-
teins. Additional proteins were included when having at least
two interactions with other landscape proteins. Serif Drawplus
4.0 (www.serif.com) was used to draw the landscape figures.
Results
In this study, we analyzed with gene enrichment approaches
and systematic literature searches published datasets of differ-
entially expressed transcripts in SN and striatum of PD pa-
tients and MPTP-treated mice that met our criteria for inclu-
sion (see Table 1 for dataset details).
Enrichment Analysis of SN mRNA Expression Data
Human PD Ingenuity enrichment analysis of the mRNAs
that, compared to healthy controls, were differentially
expressed in the SN of human PD patients revealed the sub-
categories that were most significantly enriched within the
two main functional classes, “diseases and disorders” and
“molecular and cellular functions” (Table 2). When analyzing
all differentially expressed SNmRNAs, the most significantly
enriched diseases and disorders were predominantly in the
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movement disorders domain. Similar annotations were found
for the top 5 enriched categories within the downregulated
mRNAs, while the enriched annotations within the upregulat-
ed mRNAs were not specifically related to (any) neurological
function (data not shown). At a more functional level (i.e., the
“molecular and cellular functions” category), the enriched an-
notations were all related to neuronal and/or synaptic function.
MPTP Mouse Similar Ingenuity analyses revealed the most
enriched functional categories within the mRNAs that were
differentially expressed in the SN ofMPTP-treated mice com-
pared to untreated animals (Table 2). Analyzing mRNA ex-
pression profiling data at different intervals following MPTP
treatment assessed temporal aspects of MPTP-induced neuro-
toxicity. More specifically, mice were injected four times
within an 8-day period and subsequently sacrificed for
analysis 1 and 7 days after the last treatment [7]. The enriched
diseases and disorders were, at both intervals, predominantly
in movement disorders-related domains. The enriched molec-
ular and cellular functions categories were also similar over
time, relating mainly to cell death, proliferation, and develop-
ment (both intervals), as well as to structural organization of
the cell (short interval only).
Overlap Between Human PD and MPTP Mouse The most
significantly enriched functional categories within the
mRNAs that were differentially expressed in the SN of both
PD patients andMPTP-treated mice are also shown in Table 2.
Similar to the human and mouse results mentioned above, the
enriched diseases and disorders encompass movement
disorders-related domains, while the more functional catego-
ries related to neuronal cell death, microtubule dynamics, and
Table 1 Datasets of differentially expressed transcripts in SN and striatum of PD patients and MPTP-treated mice that met the criteria for inclusion













Human M/F Moran, 2006 [31]
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8/8 SN (LCM DA
neurons)
Affymetrix Human X3P 2.0 SAM
q<0.05
31
Human M/F Lesnick, 2007 [33]
(GSE7621)
16/9 SN Affymetrix Human Genome









Human M/F Zheng, Liao, 2010 [35]
(GSE20141)
10/8 SN (LCM DA
neurons)
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Human M/F Elstner, 2011 [36] 8/9 SN (LCM DA
neurons)
Illumina WG6v1 expression chip 1.2 B&H
p<0.05
1037
Human M/F Diao, 2012 [37]
(GSE20333)















Human M/F Botta-Orfila, 2012 [39] 5/5 Putamen Affymetrix 1.0 Exon 2.0 B&H
p<0.05
186
Mouse M Miller, 2004 [7]
(GSE4788)










B&H Benjami and Hochberg, B-Y Benjami-Yekutieli, DA dopamine, F female, FC fold change, GEO gene expression omnibus, M male, LCM laser
capture microdissecton, SAM significance analysis of microarrays, SN substantia nigra
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cellular functions, including neurotransmitter synthesis and
exocytosis, as well as (neuronal) cell growth and death.
Molecular Landscape of Shared Processes in the SN
Figure 1 shows a molecular landscape of interacting proteins
encoded by the mRNAs that are differentially expressed in the
SN of both human PD patients andMPTP-treated mice. These
proteins form signaling cascades that are located in the SN
neuron presynapse, cell body, or nucleus. The main cascades
in the presynaptic landscape regulate DA synthesis, autopha-
gy, calcium signaling, vesicle trafficking, and exocytosis
(Fig. 1a). In the cell body and nucleus, particularly mitochon-
drial (dys)function and transcriptional regulation through his-
tone and nucleosome modification and its reciprocal effect on
pre-mRNA splicing are present (Fig. 1b). More specifically,
NR4A2 and SOX2, two of the five transcription factors that
are required for a DA neuron-like expression pattern, bind to
HDAC1, a histone deacetylase that interacts with many pro-
teins in the landscape. Therefore, dysregulation of any of these
processes affects DA neuron-specific expression and reduces
the number of neurons with a DA phenotype. In the Online
Resource, the landscape is described in full detail, and the
current knowledge about the functions of all landscape pro-
teins is summarized.
Enrichment Analysis of Striatal mRNA Expression Data
Human PD Similar to the SN data described above, the
disease/disorder categories that are directly related to PD-
like movement disorders and motor symptoms were signifi-
cantly enriched within the mRNAs that were found to be dif-
ferentially expressed in the striatum of PD patients (Table 3).
Furthermore, the enriched functional categories were mainly
related to neuronal functions such as (synaptic) transmission
and molecular/metal ion transport.
MPTP Mouse Again, the most significantly enriched catego-
ries were determined at various time points following MPTP
treatment. However, the respective study used a timing
Fig. 1 a Molecular landscape of interacting proteins, encoded by the
mRNAs that are differentially expressed in the SN of both human PD
patients and MPTP-treated mice, located primarily in the (pre) synapse
and axon of the DA neuron. See text and Online Resource for details. b
Molecular landscape of interacting proteins, encoded by the mRNAs that
are differentially expressed in the SN of both human PD patients and
MPTP-treated mice, located primarily in the cell body and nucleus of
the DA neuron. See text and Online Resource for details
1630 Mol Neurobiol (2016) 53:1625–1636
regimen different from the study focusing on the SN men-
tioned above. At 5 and 24 h after injection, the predominant
functional categories were implicated in (neuronal) cell death
and other acute, MPTP toxicity-related processes, including
(dys)regulation of inflammatory responses and immunity-
related cells, and endometriosis. At 72 h after MPTP injection,
the most significantly enriched categories shift towards those
enriched within the PD patient striatal data, i.e., categories
related to PD-like motor symptoms and neuronal/synaptic
function (Table 3).
Overlap Between Human PD and Mouse MPTP The most
significantly enriched categories within the mRNAs that
were differentially expressed in the striatum of both hu-
man PD patients and the MPTP mouse model comprise
a combination of the enriched “diseases and disorders”
categories identified in human PD and MPTP-treated
mice as summarized above, i.e., relating to both move-
ment disorders and epilepsy (Table 3). Indeed, the “cel-
lular and molecular functions” categories involved in
both neuronal/synaptic function and neuronal cell
growth/death are enriched within the overlapping PD
patient/MPTP mouse striatal data.
Molecular Landscape of Shared Processes in the Striatum
Figure 2 shows a molecular landscape of interacting proteins
encoded by the mRNAs differentially expressed in the stria-
tum of both human PD patients and MPTP-treated mice. PD
as well as MPTP treatment result in the degeneration of
nigrostriatal DA neurons, which decreases DA release in the
striatum and results in diminished activation of the DRD2 and
DRD3 DA receptors, in turn affecting postsynaptic striatal
protein expression and calcium signaling. Furthermore, the
majority of the proteins in this landscape regulate CREB1—
a transcription factor that is essential for DA-dependent gene
expression in the striatum—either directly via calcium signal-
ing or through activation of the ERK1/2 kinases. In the Online
Resource, the landscape is described in full detail, and the
current knowledge about the functions of the landscape pro-
teins is presented.
Discussion
This study aimed to determine the construct validity of the
MPTP mouse as a model to study human PD pathogenesis.
Fig. 1 (continued)
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First, the most important dysregulated biological processes
underlying both human PD andMPTP toxicity were identified
by enrichment analyses of published genome-wide mRNA
expression data from postmortem SN and striatum of PD pa-
tients and MPTP-treated mice. Second, proteins encoded by
the mRNAs that were differentially expressed in both PD
patients and MPTP-treated mice were integrated into molecu-
lar landscapes representing the main biological processes that
are shared by human PD and mouse MPTP toxicity. Our find-
ings demonstrate that, at the level of the SN, MPTP toxicity
has substantial relevance for PD pathogenesis. This is less
obvious for the striatum, in which important temporal effects
of MPTP toxicity were noted.
Because categories related to basal ganglia-based motor
dysfunction and neurodegeneration were enriched in the SN
of both PD patients and MPTP-treated mice, the effects of
MPTP toxicity on gene expression in the mouse SN appear
to have similar phenotypic consequences as human PD.
However, differences exist between PD and MPTP toxicity
regarding the specific (dysregulated) biological processes
involved. While in the SN of PD patients, enriched molecular
and cellular functions relate to neuronal and synaptic func-
tions, functional themes pertaining to cell growth and death
predominate in the MPTP mouse model. This discrepancy
could well reflect the differences between the protracted pro-
cesses of neurodegeneration in PD, as well as simultaneous
compensatory neuroplastic mechanisms, compared to the
acute MPTP toxicity in mice. Moreover, the biological pro-
cesses that overlap between the SN of both PD patients and
MPTP-treated mice mainly relate to neuronal/synaptic func-
tion and (neuronal) cell death, while the molecular signaling
cascades involved regulate DA synthesis and recycling, endo-
cytosis and exocytosis of (DA-containing) synaptic vesicles,
and cytoskeleton-dependent synaptic remodeling. These bio-
logical processes have been implicated in the pathogenesis of
PD before [8–10]. Proteins encoded by other differentially
expressed mRNAs are important players in other processes
that have been implicated in DA neuronal dysregulation and
death, including cytoplasmic and nuclear cascades regulating
(vesicular) trafficking [11], mitochondrial function and
Fig. 2 Molecular landscape of interacting proteins, encoded by the mRNAs that are differentially expressed in the striatum of both human PD patients
and MPTP-treated mice located in the postsynapse of a striatal neuron. See text and Online Resource for details
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apoptosis [12], proteosomal degradation (including the degra-
dation of DA neuron-specific transcription factors) [13], as
well as transcriptional, posttranscriptional and translational
processes such as histone regulation [14] and pre-mRNA
splicing [15].
As opposed to the SN findings, the categories that were
most significantly enriched within the differentially expressed
striatal mRNAs did not unequivocally overlap between hu-
man PD and mouse MPTP-induced toxicity. In PD, they are
related to PD-associated motor symptoms, but in the MPTP-
treated mouse striatum, the enriched categories depend on the
length of the time period between MPTP treatment and tran-
scriptional profiling. Early (i.e., 5 h) after MPTP injection, the
most significantly enriched disease categories within the
mouse striatal mRNA expression data are not related to motor
dysfunction but to epilepsy. Epilepsy is a known acute side
effect of MPTP injection in mice [16] and is directly linked to
the temporary presence of the active MPTP metabolite MPP+
[17]. Although observational studies have reported an associ-
ation between epilepsy and PD [18], an acute side effect of
MPTP is more likely, as MPTP treatment does not seem to
have long-lasting epileptogenic effects [19]. Indeed, in line
with a gradual reduction of MPP+ levels in the mouse brain
over time, at 24 h after injection, some of the significantly
enriched disease categories point towards an inflammatory
response, while at 72 h, they are related to motor dysfunction
and neurodegeneration. A similar pattern is observed for the
molecular and cellular functions, where at 5 h after injection,
the enriched functions are mainly related to cell growth and
death, shifting to cellular organization- and morphology-
related functions at later time points. Although direct compar-
ison of studies is challenging due to different injection regi-
mens, these findings may suggest that in the striatum—more
clearly than in the SN—the MPTP-induced expression chang-
es and the molecular signaling cascades that are affected by
these expression changes are not consistent but change to-
wards more PD-relevant processes over time. The overlap
between PD andMPTP-treated mice in biofunctions of striatal
mRNAs, encompassing both “acute” toxicity-related and
“chronic” PD-related categories, is corroborated by the mo-
lecular landscape. In this landscape, part of the affected bio-
logical processes and functions appears directly related to di-
minished DA striatal innervation through postsynaptic DA
receptors. In addition, there seems to be a strong convergence
on the regulation of intracellular calcium levels as well as
CREB1-related signaling, which have both been functionally
linked to epilepsy before [20]. Again, it remains unsure
whether these signaling cascades are affected by the reduced
DA innervation from the presynaptic SN neuron or that they
merely reflect an acute “side effect” of MPTP rather than
having much direct relevance for PD pathogenesis. The find-
ing of the endometriosis-related enrichment in mice may be
related to the fact that only female mice were used, while for
the human studies, bothmale and female subjects were includ-
ed. However, since 8 out of the 14 proteins with the annotation
“endometriosis” are also present in the annotated category
“dyskinesia”, the “endometriosis” enrichment may be due to
either a true gender effect, an enrichment of genes involved in
movement dysfunction-related processes, or both.
Thus, our transcriptome analyses and molecular landscapes
indicate that the MPTP mouse constitutes a valid model for the
chronic molecular and pathological changes that occur in the SN
of PD patients and hence of the PD phenotype that is associated
with these changes. However, this is less obvious for the striatum,
because early after MPTP injection, enriched categories and
functions encompass mainly processes that are not directly relat-
ed to PD. It appears that human PD pathogenesis in the striatum
is better recapitulated at the molecular level in the MPTP-treated
mouse model 72 h postinjection and perhaps even later. Effects
of the level of chronicity of the dosing regimen on markers of
Fig. 3 Proposed fundamental
mechanisms underlying the
degeneration of dopaminergic
neurons in Parkinson’s disease
and mouse MPTP toxicity. The
numbers denote the sequence of
events in Parkinson’s disease and
the MPTP mouse, respectively.
See text for further details
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DA neurotransmission—e.g., TH expression and striatal DA
levels—and behavioral outcome have been reported before
[21–23], but specific effects on the transcriptome have not been
addressed. In this respect, assessing the relationship between the
temporal expression patterns in human PD patients and their
disease duration would be of interest, similar to the analyses that
were performed on the mouse-MPTP data. Unfortunately, for the
reported human expression studies, disease duration data were
not available for all cases.
In addition to the acutely toxic nature of early MPTP-induced
pathology, there may be several other explanations for the appar-
ent discrepancy between the striatal PD pathogenesis and MPTP
toxicity. First, presynaptic DAdenervationmay result in enriched
processes that are different between humans and mice due to
species specificity. For example, similar degrees of DA degener-
ation in humans and mice do not result in similar phenotypic
severity [24] and clinical phenotypes differ as mice do not show
the tremor often seen in patients. Second, chronic compensating
processes including adaptive neuroplasticity could play an im-
portant role in PD but less in MPTP-treated mice. In PD, these
processes may be linked to the synaptic transmission- and mo-
lecular transport-related functions that are enriched in striatal
mRNAs. The acutely toxic nature of MPTP would not allow
for such an adaptation. Finally, it should be noted that, despite
the high degree of overlap, the absolute number of differentially
expressed mRNAs that overlap between human PD striatum and
MPTP mouse striatum is low, perhaps prohibiting the detection
of statistically relevant enrichment.
The principal differences between the chronological orders of
events in PD-linked neurodegeneration versus MPTP-induced
toxicity are summarized in Fig. 3. In PD, a number of molecular
mechanisms in presynaptic SN neurons—including vesicular
trafficking and exocytosis, mitochondrial apoptosis, as well as
several transcriptional and translational processes—cause
neuronal/synaptic dysfunction and cell death, which is followed
by chronic, postsynaptic compensatory mechanisms in the stria-
tum. In contrast, MPTP is taken up readily as MPP+ through the
DA transporter (DAT) in presynaptic SN neuron terminals [25],
causing toxicity and sequestration of MPP+ into synaptic vesi-
cles [26]. MPP+ also reaches the cell body of presynaptic SN
neurons through retrograde axonal transport [27], which in turn
causes neuronal death through mitochondrial accumulation and
electron transport chain inhibition, inducing neuronal apoptosis
[28]. This relatively rapid cell death causes more acute compen-
satory effects in the postsynaptic striatal neurons [29].
Together, our findings provide further evidence that the mo-
lecular changes in the SN of MPTP-treated mice correspond to
the observed alterations in the SN of PD patients. However, for a
proper reflection of the molecular changes occurring during PD
pathogenesis in the striatum, the time point of studying the
changes following MPTP treatment is crucial. Further tran-
scriptome studies are needed to determine whether waiting lon-
ger than 72 hwould indeed provide a better construct validity for
human PD pathogenesis and whether there is an optimal time
frame following MPTP injection to assess striatal PD pathology
in theMPTPmousemodel. Such knowledgewill have important
practical implications for the use of theMPTPmouse as a model
for PD and for PD drug testing.
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